Gilead Sciences is a biopharmaceutical company dedicated to advancing therapeutics in areas of unmet medical need. Founded in 1987, the company has a rich history of innovation, particularly in the fields of HIV, liver diseases, and oncology. Gilead's investment philosophy centers on developing transformative medicines that improve patient outcomes and quality of life.

Notable achievements include the development of antiretroviral therapies that have significantly impacted HIV treatment and the introduction of antiviral drugs for hepatitis C that have revolutionized care. The company's areas of focus encompass virology, oncology, and inflammation, with a commitment to addressing complex diseases through scientific excellence and patient-centric approaches. Key differentiators include a robust research and development pipeline, strategic partnerships, and a global presence that enables access to its therapies worldwide.

Gilead's geographic focus spans North America, Europe, and Asia, with a strong emphasis on expanding access to medicines in low- and middle-income countries. The company maintains an active presence on social media platforms, including Twitter, LinkedIn, and Facebook, to engage with the global community and share updates on its initiatives.